We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel).
- Authors
Khan, M S; El-Khouly, F; Davies, P; Toumpanakis, C; Caplin, M E
- Abstract
Somatostatin analogues are the mainstay of therapy for malignant carcinoid syndrome. There is clear evidence that the once monthly intramuscular formulation, Octreotide LAR, controls symptoms of carcinoid syndrome, and recent data also suggests an antitumour effect. There is limited data on prolonged release Lanreotide (Somatuline Autogel, Ipsen Pharma Biotech, Signes, France) and no long-term data to date.
- Publication
Alimentary pharmacology & therapeutics, 2011, Vol 34, Issue 2, p235
- ISSN
1365-2036
- Publication type
Journal Article
- DOI
10.1111/j.1365-2036.2011.04693.x